Loading...
•
Dec 31, 2025
Immuneering Q4 2025 Earnings Report
Immuneering Q4 2025 Earnings Report
Key Takeaways
Immuneering reported a significant improvement in its cash position following financing efforts, ending the year with $217 million. The company achieved positive Phase 2a clinical data in pancreatic cancer and secured regulatory alignment for its upcoming Phase 3 trial, while narrowing its quarterly net loss compared to the prior year.
Observed 64% overall survival at 12 months in Phase 2a trial for first-line pancreatic cancer, significantly exceeding the 35% standard of care benchmark.
Secured alignment with both FDA and EMA on the design of the pivotal Phase 3 MAPKeeper 301 trial.
Cash runway extended into 2029 following successful financing, with $217 million in cash and marketable securities.
Reduced quarterly R&D expenses by 38% year-over-year due to prioritized spending on atebimetinib and reduced preclinical activities.
Forward Guidance
Immuneering expects its current cash position to fund operations into 2029 and is focused on advancing atebimetinib into a pivotal Phase 3 trial and new clinical combinations.
Positive Outlook
- Cash runway expected to last into 2029.
- On track to report updated survival data from over 50 pancreatic cancer patients in 1H 2026.
- Dosing of first patient in pivotal Phase 3 MAPKeeper 301 trial expected in mid-2026.
- Planned initiation of Phase 2 trial in RAS-mutant NSCLC with Libtayo in 2H 2026.
- Updated circulating tumor DNA data expected in Q2 2026.
Challenges Ahead
- Company continues to incur significant operating losses.
- Increased G&A expenses due to higher employee-related costs and professional fees.
- Reliance on successful clinical outcomes for a single lead candidate (atebimetinib).
- Future funding may still be required despite current runway.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...